Kevzara (sarilumab) — CareFirst (Caremark)

Initial criteria

• Diagnosis confirmed by temporal artery biopsy or cross-sectional imaging OR acute-phase reactant elevation (high ESR and/or CRP)

Reauthorization criteria

• Positive clinical response as evidenced by improvement or maintenance of disease control per physician-assessed outcome

Approval duration

12 months